Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations
Ilya Ayzenberg, Robert Hoepner, Ingo Kleiter Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany Abstract: Fingolimod (FTY720), an immunotherapeutic drug targeting the sphingosine-1-phosphate receptor, is a widely used medication for relapsing-remitting multiple scler...
Saved in:
Main Authors: | Ayzenberg I (Author), Hoepner R (Author), Kleiter I (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
by: Prosperini L, et al.
Published: (2016) -
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
by: Dörr J, et al.
Published: (2016) -
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
by: Pablo Bascuñana, et al.
Published: (2020) -
CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS
by: Rizaldy Taslim Pinzon, et al.
Published: (2017) -
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021)